HLA
ALGS icon

Hamilton Lane Advisors’s Aligos Therapeutics ALGS Stock Holding History

Hamilton Lane Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-485
Closed -$247K – 77
2021
Q2 		$247K Buy
+485
New +$309K 0.08% 71

Other funds holding ALGS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Hamilton Lane Advisors's ALGS Position: Q3 2021 in Review

Hamilton Lane Advisors sold out of Aligos Therapeutics (ALGS) in Q3 2021, closing a stake of 485 shares — an estimated $247K sold.

Hamilton Lane Advisors first reported a position in ALGS in Q2 2021 and held it in 1 quarter. The position peaked at $247K in Q2 2021. 68 funds tracked by Wall St. Rank hold ALGS as of Q3 2021.

  • Hamilton Lane Advisors reported no remaining Aligos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 485 Aligos Therapeutics shares in Q3 2021, an estimated $247K.
  • Hamilton Lane Advisors first reported a position in Aligos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Hamilton Lane Advisors's Aligos Therapeutics position peaked at $247K in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2021.

Based on Hamilton Lane Advisors's 13F filing for Q3 2021, filed 14 Oct 2021.